Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$512 Mln
P/E Ratio
--
P/B Ratio
3.42
Industry P/E
--
Debt to Equity
0.18
ROE
-0.22 %
ROCE
-9.02 %
Div. Yield
0 %
Book Value
2.28
EPS
-0.52
CFO
$216.53 Mln
EBITDA
$400.75 Mln
Net Profit
$-395.99 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bioventus Inc. Class A (BVS)
| -29.05 | -17.50 | -28.50 | 87.19 | -15.32 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Bioventus Inc. Class A (BVS)
| 98.12 | 101.92 | -81.99 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.66 | 10,562.04 | 12.43 | 12.69 | |
| 72.81 | 10,050.19 | 97.07 | 2.52 | |
| 162.97 | 8,847.72 | -- | -25.23 | |
| 296.92 | 11,609.25 | 277.57 | 3.65 |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular... and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina. Address: 4721 Emperor Boulevard, Durham, NC, United States, 27703 Read more
Senior VP & CFO
Mr. Mark L. Singleton
Senior VP & CFO
Mr. Mark L. Singleton
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bioventus Inc Class A (BVS) stood at $ 728 Mln as on 31-Dec-24
The share price of Bioventus Inc Class A (BVS) is $7.45 (NASDAQ) as of 29-Apr-2025 12:39 EDT. Bioventus Inc Class A (BVS) has given a return of -15.32% in the last 3 years.
Bioventus Inc Class A (BVS) has a market capitalisation of $ 512 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Bioventus Inc Class A (BVS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bioventus Inc Class A (BVS) and enter the required number of quantities and click on buy to purchase the shares of Bioventus Inc Class A (BVS).
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina. Address: 4721 Emperor Boulevard, Durham, NC, United States, 27703
The CEO & director of Mr. Mark L. Singleton. is Bioventus Inc Class A (BVS), and CFO & Sr. VP is Mr. Mark L. Singleton.
There is no promoter pledging in Bioventus Inc Class A (BVS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Bioventus Inc. Class A (BVS) | Ratios |
|---|---|
|
Return on equity(%)
|
-20.86
|
|
Operating margin(%)
|
-17.29
|
|
Net Margin(%)
|
-5.85
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bioventus Inc Class A (BVS) was $0 Mln.
$0.02
(
